UOC
NBIX icon

UBS O'Connor’s Neurocrine Biosciences NBIX Stock Holding History

UBS O'Connor’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-23,111
Closed -$3.15M – 416
2024
Q4 		$3.15M Sell
23,111
-8,559
-27% -$1.06M 0.08% 117
2024
Q3 		$3.65M Buy
31,670
+15,370
+94% +$2.11M 0.09% 120
2024
Q2 		$2.24M Buy
16,300
+2,300
+16% +$315K 0.06% 176
2024
Q1 		$1.93M Sell
14,000
-5,796
-29% -$792K 0.06% 179
2023
Q4 		$2.61M Sell
19,796
-14,002
-41% -$1.61M 0.08% 139
2023
Q3 		$3.8M Sell
33,798
-5,000
-13% -$527K 0.07% 159
2023
Q2 		$3.66M Buy
38,798
+7,616
+24% +$744K 0.08% 167
2023
Q1 		$3.16M Buy
+31,182
New +$3.24M 0.07% 199
2022
Q4 		– Sell
-17,003
Closed -$1.81M – 206
2022
Q3 		$1.81M Sell
17,003
-20,200
-54% -$2.05M 0.02% 655
2022
Q2 		$3.63M Buy
+37,203
New +$3.43M 0.04% 424
2016
Q3 		– Sell
-61,715
Closed -$2.81M – 468
2016
Q2 		$2.81M Sell
61,715
-51,829
-46% -$2.39M 0.06% 227
2016
Q1 		$4.49M Buy
+113,544
New +$4.51M 0.08% 217
2014
Q4 		– Sell
-100,000
Closed -$1.57M – 692
2014
Q3 		$1.57M Buy
100,000
+35,000
+54% +$523K 0.03% 306
2014
Q2 		$965K Sell
65,000
-31,671
-33% -$447K 0.01% 332
2014
Q1 		$1.56M Buy
+96,671
New +$1.65M 0.03% 302
2013
Q4 		– Sell
-73,900
Closed -$837K – 461
2013
Q3 		$837K Buy
+73,900
New +$1.02M 0.02% 305

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS O'Connor's NBIX Position: Q1 2025 in Review

UBS O'Connor sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 23,111 shares — an estimated $3.15M sold.

UBS O'Connor first reported a position in NBIX in Q3 2013 and held it in 16 quarters. The position peaked at $4.49M in Q1 2016. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • UBS O'Connor reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 23,111 Neurocrine Biosciences shares in Q1 2025, an estimated $3.15M.
  • UBS O'Connor first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 16 quarters.
  • UBS O'Connor's Neurocrine Biosciences position peaked at $4.49M in Q1 2016.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.